AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02202057 — intervention group
Intervention type: OTHER
Intervention: Respiratory resistive load on inhalation
Description: The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in.
Study NCT02202057 — intervention group
Intervention type: OTHER
Intervention: Fluoroscopic swallowing evaluation
Description: Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
Study NCT03166904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib(AZD2014)
Description: Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
Study NCT00191646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles
Study NCT00191646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles
Study NCT00810381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
Study NCT00810381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide-Dinitrate
Description: intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
Study NCT00810381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium-nitroprusside
Description: intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
Study NCT00810381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline solution (control substance)
Description: intravenous infusion, infusion period 120 minutes
Study NCT01739673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultraviolet-A and riboflavin
Study NCT03139097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT03599921 — intervention group
Intervention type: BEHAVIORAL
Intervention: Family-based treatment
Description: Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness.
Study NCT03599921 — intervention group
Intervention type: BEHAVIORAL
Intervention: Enhanced Cognitive behavioral therapy
Description: Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed.
Study NCT03599921 — intervention group
Intervention type: BEHAVIORAL
Intervention: Family-based treatment modified for ARFID
Description: Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed.
Study NCT03599921 — intervention group
Intervention type: BEHAVIORAL
Intervention: FBT + UP for ARFID
Description: Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses.
Study NCT00870935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon catheter
Description: Hysterosalpingography is performed using intrauterine balloon catheter
Study NCT00870935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Description: Hysterosalpingography is performed using intrauterine balloon catheter
Study NCT00870935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical vacuum cup
Description: Hysterosalpingography is performed using cervical vacuum cup
Study NCT00870935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical vacuum cup
Description: Hysterosalpingography is performed using cervical vacuum cup
Study NCT00714051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fall prevention training
Description: Training on a specialized treadmill that produced trip-simulating perturbations (movements.
Study NCT00714051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants walked on a treadmill at a self-selected speed once per week for four weeks.
Study NCT02992548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Study NCT00105157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518
Description: MK0518 oral tablets 200 mg b.i.d, for 24 weeks
Study NCT00105157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518
Description: MK0518 oral tablets 400 mg b.i.d, for 24 weeks
Study NCT00105157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518
Description: MK0518 oral tablets 600 mg b.i.d, for 24 weeks
Study NCT00105157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to MK0518, oral tablet b.i.d, for 24 weeks
Study NCT00967395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing
Description: Healing in our study is given be a healer no-touch, who just has to be present in the room.
Study NCT00967395 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham healing
Description: Sham Healing in our study is given be a student no-touch, who just has to be present in the room.
Study NCT00365690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-administered coping improvement therapy
Description: Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
Study NCT00365690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-administered supportive-expressive therapy
Description: Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
Study NCT00365690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual therapy
Description: Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
Study NCT04525898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone
Description: The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
Study NCT04525898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
Study NCT02246296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard F75 Milk
Description: This is the standard F75 milk used worldwide (Control group)
Study NCT02246296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified F75 Milk
Description: This is the experimental group
Study NCT03237156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsules.
Study NCT03237156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-906 Placebo
Description: Placebo capsules.
Study NCT03105297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype nasal dilator strip
Description: External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
Study NCT03105297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No strip
Study NCT00216060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Daily oral risedronate combined with androgen deprivation
Study NCT00216060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral placebo combined with androgen deprivation
Study NCT02404558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection
Study NCT02404558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection
Study NCT02581917 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of PBMC samples
Study NCT02581917 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Undergo metabolic analysis
Study NCT00860145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiosurgery
Description: The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
Study NCT00860145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: temporal lobectomy
Description: The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
Study NCT01268839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25mg tablet once daily for 28 days
Study NCT01268839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25mg tablet once daily for 14 days
Study NCT01268839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600mg tablet once daily for 14 days
Study NCT01386125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
Study NCT01386125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MFNS
Description: Two sprays in each nostril BID for up to 16 weeks
Study NCT01630616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: single oral dose, tablets, 10 or 50 mg
Study NCT01630616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose, tablets
Study NCT03359720 — intervention group
Intervention type: OTHER
Intervention: no intervention survey
Description: survey
Study NCT04125914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Record food intake
Study NCT04125914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-mail
Description: Receive e-mails
Study NCT03200145 — intervention group
Intervention type: OTHER
Intervention: ACP intervention
Description: The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~1. - Attention to the person based on:~   * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~  * Respect and acknowledge of the person.~  * Promotion of the autonomy.~  * Personalized treatment, with tailored attention and integrative cures~  * Protection of physical well-being, preventing damages and risks and promoting healthy habits.~  * Promotion of independence on daily activities.~  * Protection of privacy and personal matters~2. - Positive environment based on:~   * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~  * Social relationships, with proximity and collaboration with families.~  * Friendly organization, with empathetic professionals empowering users.
Study NCT01156467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)
Description: Treatment with Edi-catheter
Study NCT01156467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group, ventilation with i-Servo or Stephanie
Description: Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
Study NCT02219100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home administration of 200 mg mifepristone
Description: Home administration of 200 mg mifepristone
Study NCT04824287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle exercise
Description: pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
Study NCT02489487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500 40 mg
Study NCT02489487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600 mg
Study NCT02489487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg
Study NCT02489487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg Raltegravir
Study NCT04290312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mastiha oil
Description: After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing \~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
Study NCT00650234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fasting
Study NCT00650234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR Tablets 500 mg
Description: 500mg, single dose fasting
Study NCT02966041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
Study NCT02966041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
Study NCT04597164 — intervention group
Intervention type: OTHER
Intervention: Artificial liver support system
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
Study NCT02497300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Study NCT02497300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Study NCT01483807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment - Blocked
Description: Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
Study NCT01483807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment - Random
Description: A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
Study NCT01960673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA proseal
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
Study NCT01960673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: igel LMA
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
Study NCT01960673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air Q LMA
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
Study NCT01960673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambu LMA
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
Study NCT02819518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT00613730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous administration